Science Explorer Back to mapMap

Most cited papers from VLP Therapeutics (United States)

What are the most cited papers from VLP Therapeutics (United States)?

The most cited paper from VLP Therapeutics (United States) is "Expression and function of periostin‐isoforms in bone" (Judith Litvin, Abdulhafez Selim, Michael O. Montgomery et al., 2004), with 182 citations. Next come "Mixed Messages" (179) and "Structural studies of Chikungunya virus maturation" (156).

Showing 38 of 38 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Expression and function of periostin‐isoforms in bone Judith Litvin, Abdulhafez Selim, Michael O. Montgomery et al. · Journal of Cellular Biochemistry 14 Jun 2004 182
2 Mixed Messages Kenneth B. Margulies, Sunil Matiwala, Carla Cornejo et al. · Circulation Research Open access 18 Feb 2005 179
3 Structural studies of Chikungunya virus maturation Moh Lan Yap, Thomas Klose, Akane Urakami et al. · Proceedings of the National Academy of Sciences Open access 4 Dec 2017 156
4 Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial Sean Bennett, James M McCarty, Roshan Ramanathan et al. · The Lancet Infectious Diseases 13 Jun 2022 81
5 An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design Akane Urakami, Mya Myat Ngwe Tun, Meng Ling Moi et al. · Journal of Virology Open access 27 Sep 2017 78
6 Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity Feng Long, Rachel H. Fong, S. Kyle Austin et al. · Proceedings of the National Academy of Sciences Open access 26 Oct 2015 60
7 Clinical trials of self-replicating RNA-based cancer vaccines Michael Andrew Morse, Erika J. Crosby, Jeremy Meyer Force et al. · Cancer Gene Therapy Open access 10 Feb 2023 57
8 Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio Erika J. Crosby, Amy C. Hobeika, Donna Niedzwiecki et al. · Journal for ImmunoTherapy of Cancer Open access Nov 2020 54
9 Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus Akane Urakami, Atsuko Sakurai, Momoko Ishikawa et al. · Clinical and Vaccine Immunology Open access 18 May 2017 50
10 Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study Wataru Akahata et al. · Cell Reports Medicine Open access Aug 2023 43
11 saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern Mai Komori, Takuto Nogimori, Amber L. Morey et al. · Nature Communications Open access 19 May 2023 39
12 Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine Masayuki Aboshi, Kenta Matsuda, Daisuke Kawakami et al. · iScience Open access 22 Jan 2024 37
13 Reassessing therapeutic antibodies for neglected and tropical diseases Rob Hooft van Huijsduijnen, Somei Kojima, Dee A. Carter et al. · PLoS neglected tropical diseases Open access 30 Jan 2020 34
14 Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission Jason C. Porta, Vidya Mangala Prasad, Cheng‐I Wang et al. · Journal of Virology Open access 4 Nov 2015 33
15 A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates Daniel Thoresen, Kenta Matsuda, Akane Urakami et al. · Journal of Virology Open access 22 Apr 2024 31
16 Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine Mai Komori, Amber L. Morey, Andrés A. Quiñones-Molina et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access Nov 2023 23
17 Lyophilized SARS-CoV-2 self-amplifying RNA vaccines for microneedle array patch delivery Madison M. Driskill, Ian A. Coates, Paul Joshua Hurst et al. · Journal of Controlled Release Open access 9 Jun 2025 17
18 The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines Denny Kim, James S. Robertson, Jean‐Louis Excler et al. · Vaccine Open access 19 Jun 2020 17
19 The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines RICHARD C. CONDIT, Denny Kim, James S. Robertson et al. · Vaccine Open access 6 Sep 2020 9
20 Incorporation of 5-methylcytidine alleviates RIG-I–mediated innate immune responses to a self-amplifying RNA vaccine Wataru Akahata, Mai Komori, Amber L. Morey et al. · Science Translational Medicine Open access 12 Nov 2025 8
21 Pharmacological Effects of ATI22-107 [2-(2-{2-[2-Chloro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-acetylamino}-ethoxymethyl)-4-(2-chloro-phenyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic Acid Dimethyl Ester)], a Novel Dual Pharmacophore, on Myocyte Calcium Cycling and Contractility Albert S. Jung, Michael P. Quaile, Geoffrey D. Mills et al. · Journal of Pharmacology and Experimental Therapeutics 15 Jan 2005 4
22 Safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base Masayuki Aboshi, Daisuke Kawakami, Kaoru Kono et al. · iScience Open access 22 Jan 2026 2
23 Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals Masayuki Aboshi, Kenta Matsuda, Daisuke Kawakami et al. · medRxiv PreprintOpen access 6 Sep 2023 2
24 A global map of the Zika virus phosphoproteome reveals host-driven regulation of viral budding and cytopathogenicity Inessa Manuelyan, Anna M. Schmoker, Boyd L. Yount et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 25 Nov 2021 2
25 Cholesterol-containing ionizable lipids for safe and efficient mRNA delivery via lipid nanoparticles Liang Xie, Haiyang Li, Jiangsheng Xu et al. · New Journal of Chemistry 2026 1
26 Coordinated Temporal Dynamics of Glucocorticoid Receptor Binding and Chromatin Landscape Drive Transcriptional Regulation Diana A. Stavreva, Sohyoung Kim, Saori Fujiwara et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 25 Apr 2026 1
27 Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing anchored RBD: a randomised, observer-blind, phase 1 study Wataru Akahata et al. · medRxiv PreprintOpen access 22 Nov 2022 1
28 ClC-2 Chloride Channels John Cuppoletti, Danuta H. Malinowska, Ryuji Ueno · Physiology in health and disease Book chapter 2020 1
29 Identification of myocardial recovery genes with a multi-comparison PRISM Kenneth B. Margulies, Tara Eskandari, Sunil Matiwala et al. · Journal of Cardiac Failure 12 Sep 2003 1
30 P4‐291: Identification and validation of a blood‐based transcriptomic signature (AclarusDx) in the diagnosis of Alzheimer's disease Rich Einstein, Olivier Sol, Pascale Beurdeley et al. · Alzheimer s & Dementia Jul 2011 1
31 A global map of the Zika virus phosphoproteome reveals host-driven regulation of viral particle release and cytopathogenicity Inessa Manuelyan, Anna M. Schmoker, Boyd L. Yount et al. · PLoS Pathogens Open access 3 Sep 2026 0
32 Proof-of-Concept Development and Preclinical Evaluation of a Microarray Patch Platform for Codelivery of Multiple Broadly Neutralizing Antibodies for HIV Prevention M. Melissa Peet, Vivek Agrahari, Parbeen Singh et al. · Molecular Pharmaceutics Open access 14 Jul 2026 0
33 Spatial Tail Design in Ionizable Lipids Enhances the Safety and Efficacy of mRNA Delivery Hui Li, Chongyu Tian, Weining Kong et al. · Small Methods Open access 26 Jun 2026 0
34 A chikungunya virus-like particle vaccine reduces chikungunya disease in cynomolgus macaques and protection is mediated by antibody transferred from vaccinated humans Lark L. Coffey et al. · npj Vaccines Open access 18 Mar 2026 0
35 Alphavirus replicon particle expressing IL-12 reprograms tumor-associated macrophages and neutrophils and induces anti-tumor immunity Momoko Ishikawa, Dhanya K. Nambiar, Jaya Sastri et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 11 Aug 2025 0
36 Antigen Dose and Persistence Contribute to Induction of a Durable HIV-1-Specific Neutralizing Antibody Response Mark Connors et al. · Research Square PreprintOpen access 23 Dec 2024 0
37 A Tetravalent Dengue Virus-like Particle Vaccine Induces High levels of Neutralizing Antibodies and Inhibits Dengue Replication in Non-Human Primates Daniel Thoresen, Kenta Matsuda, Akane Urakami et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 16 Oct 2023 0
38 P4‐290: Blood transcriptomic signatures of Alzheimer's patients treated with a novel Alzheimer's disease drug, EHT 0202, allow identification of novel potential biomarkers correlated with treatment response and efficacy Laurent Désiré, Jennyfer Carriere, Elodie Blondiaux et al. · Alzheimer s & Dementia Jul 2011 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.